096 - Ozempic / Running for Depression / The Case of the Baseball Player's Heart

The Body of Evidence

What does the body of evidence say on Ozempic and its impact on diabetes and obesity? Plus: can you trade in your antidepressant for a jog, and Chris returns to the hot seat to diagnose a teenage boy who fell during a baseball game!

Block 1:

(2:22) Ozempic/Wegovy: GLP-1 receptor agonists; the difference between them; Mounjaro; Trulicity; diabetes biology; glucagon-like peptides 1 and 2; the problem with GLP-1; DPP4 inhibitors

Block 2:

(12:33) Ozempic/Wegovy: The venom of the Gila monster; how semaglutide became a blockbuster drug; weight loss; the numerous clinical trials; the impact on the stock prices of dialysis companies; downsides; the Internet craze

Block 3:

(27:03) Is running as beneficial for depression as medication?

Block 4:

(36:42) The case of the baseball player’s heart

* Jingle by Joseph Hackl

* Theme music: “Fall of the Ocean Queen“ by Joseph Hackl

* Assistant researcher: Aigul Zaripova

To contribute to The Body of Evidence, go to our Patreon page at: http://www.patreon.com/thebodyofevidence/.

To make a one-time donation to our show, you can now use PayPal! https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE

Patrons get a bonus show on Patreon called “Digressions”! Check it out!

References:

1) History of GLP-1 receptor agonists: https://www.statnews.com/2023/09/30/weight-loss-ozempic-nobel-prize-science/

2) Liraglutide vs. exenatide: https://doi.org/10.1016/S0140-6736(12)61267-7

3) Meta-analysis of GLP-1 receptor agonists: https://doi.org/10.1111/dom.12849

4) A brief summary of the SUSTAIN studies, all 11 of them, which demonstrated the efficacy of semaglutide and its cardiovascular benefit: https://diabetes.medicinematters.com/semaglutide/type-2-diabetes/a-quick-guide-to-the-sustain-trials/12206922

5) A brief summary of the STEP trials, all 10 of them, which tested semaglutide as a weight loss medications even in non-diabetics: https://diabetes.medicinematters.com/semaglutide/obesity/quick-guide-step-trials/18854832

6) Announcement that the FLOW trial is being stopped prematurely: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166327 & https://www.investors.com/news/technology/novo-nordisk-stock-pops-after-hinting-weight-loss-drug-treats-kidney-disease/

7) GI side effects of GLP-1 receptor agonists: https://doi.org/10.1001/jama.2023.19574

8) Gid M-K’s Slate article: https://slate.com/technology/2023/10/exercise-depression-anxiety-treatment-effectiveness-ssris-research.html

9) Study on running to treat depression: https://www.sciencedirect.com/science/article/pii/S0165032723002239?via%3Dihub#s0065:~:text=https%3A//doi.org/10.1016/j.jad.2023.02.064

10) Details on the DEA-Quebec app to find an AED near you: https://www.jacquesdechamplain.com/en/major-update-to-the-dea-quebec-application/

11) Government of Canada’s definition of a pesticide: https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/environmental-contaminants/human-biomonitoring-resources/glyphosate-in-people.html

It’s Not Twitter, But It’ll Do:

1) Jonathan’s article on how natural health products and dietary supplements are regulated: https://www.mcgill.ca/oss/article/critical-thinking-health-and-nutrition/false-reassurance-dietary-supplement-regulation

2) Jonathan’s article on fentanyl: https://www.mcgill.ca/oss/article/medical-critical-thinking/you-wont-die-touching-fentanyl

3) Chris’ article in Medscape about the COSMOS study: https://www.medscape.com/viewarticle/996926

4) Chris’ Gazette article on coated vs. uncoated aspirin: https://montrealgazette.com/opinion/columnists/christopher-labos-the-bare-facts-about-coated-aspirin